SUBSCRIBE
SUBSCRIBE
News   Drug Development

Amgen (JOBS) Trial Finds No Heart Benefit with Aranesp

August 26, 2009 | 
1 min read
Bookmark and Share

Reuters -- A trial of Amgen Inc's Aranesp found the blockbuster anemia drug does not have a significant effect on the risk of heart attack and other cardiac events in kidney patients, the company said on Tuesday.
Clinical research Phase III Postmarket research
Amgen
MORE ON THIS TOPIC
Podcast
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
September 10, 2025
 · 
1 min read
 · 
Jef Akst
Hand holding a lung shape symbol against a blue background. World tuberculosis day, world no tobacco day, lung cancer, pulmonary hypertension, pneumonia
Lung cancer
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC
September 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Collage art of a hand touching a cat. Modern and creative design with surreal style. Perfect for use in posters, editorial design, social media, digital art, and contemporary art projects
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
September 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Modern data center with AI server racks connected by glowing blue lines, representing artificial intelligence, advanced computing, and data processing.
Drug Development
If Data Is the New Oil, AI Is the Refinery
September 8, 2025
 · 
5 min read
 · 
Lori Ellis